Quarterly Result14 May 2026, 05:11 pm
Senores Pharma FY26 Revenue Up 62% to ₹664 Cr
AI Summary
Senores Pharmaceuticals Ltd. reported a correction to its previously released media statement regarding the audited financial results for the quarter and fiscal year ending March 31, 2026. The corrected release highlights strong financial performance, with total income for FY26 reaching ₹664 Cr, a 62% increase year-over-year. EBITDA grew by 96% to ₹200 Cr, and PAT increased by 108% to ₹122 Cr. The company also noted significant growth in regulated markets, emerging markets, and branded generics businesses, along with strategic acquisitions and joint ventures to expand its market presence.
Key Highlights
- FY26 total income increased by 62% to ₹664 Cr, with EBITDA up 96% and PAT up 108%.
- Regulated Markets revenue grew by 74.6% to ₹427.4 Cr in FY26.
- Branded Generics revenue surged by 385.3% in FY26.
- Acquired 51% stake in Zoraya Pharmaceuticals and 75% stake in Apnar Pharmaceuticals to strengthen vertical integration.
- Entered a 70% joint venture, Amerisyn, to access the U.S. Federal Market.
Price Impact
More from SENORES